Protara Therapeutics (TARA) Projected to Post Earnings on Thursday

Protara Therapeutics (NASDAQ:TARA) is expected to release its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect Protara Therapeutics to post earnings of ($0.36) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.

Protara Therapeutics (NASDAQ:TARA) last announced its quarterly earnings data on Tuesday, March 10th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). On average, analysts expect Protara Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Protara Therapeutics Stock Performance

Shares of TARA opened at $5.66 on Thursday. The firm has a market cap of $311.64 million, a price-to-earnings ratio of -4.29 and a beta of 1.53. Protara Therapeutics has a fifty-two week low of $2.77 and a fifty-two week high of $7.82. The firm has a 50 day moving average price of $5.37 and a 200-day moving average price of $5.71.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on TARA. JPMorgan Chase & Co. began coverage on shares of Protara Therapeutics in a report on Wednesday, March 4th. They issued an “overweight” rating and a $27.00 price objective for the company. HC Wainwright upped their price target on shares of Protara Therapeutics from $23.00 to $27.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Protara Therapeutics in a report on Tuesday, April 21st. Piper Sandler began coverage on shares of Protara Therapeutics in a report on Wednesday, January 7th. They set an “overweight” rating and a $24.00 price target for the company. Finally, TD Cowen reiterated a “buy” rating on shares of Protara Therapeutics in a report on Tuesday, March 10th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Protara Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $24.75.

Insider Buying and Selling

In other Protara Therapeutics news, insider Jacqueline Zummo sold 22,598 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $5.26, for a total value of $118,865.48. Following the completion of the sale, the insider directly owned 95,961 shares in the company, valued at $504,754.86. This trade represents a 19.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 8.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Virtu Financial LLC purchased a new position in shares of Protara Therapeutics during the 4th quarter worth approximately $368,000. ADAR1 Capital Management LLC grew its position in shares of Protara Therapeutics by 3,127.4% in the 4th quarter. ADAR1 Capital Management LLC now owns 1,136,799 shares of the company’s stock worth $6,059,000 after buying an additional 1,101,576 shares during the period. XTX Topco Ltd purchased a new stake in shares of Protara Therapeutics in the 4th quarter worth about $615,000. Sphera Funds Management LTD. purchased a new stake in shares of Protara Therapeutics in the 4th quarter worth about $3,464,000. Finally, Quadrature Capital Ltd grew its position in shares of Protara Therapeutics by 39.4% in the 4th quarter. Quadrature Capital Ltd now owns 24,184 shares of the company’s stock worth $129,000 after buying an additional 6,838 shares during the period. Hedge funds and other institutional investors own 38.13% of the company’s stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.